NCT04413539View on ClinicalTrials.gov

Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living with Sickle- Cell Disease in France

CompletedOBSERVATIONAL
Enrollment

1,088

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

April 27, 2021

Study Completion Date

April 27, 2021

Conditions
Sickle-cell Disease (SCD)
Trial Locations (1)

Unknown

Centre de références syndromes drépanocytaires majeurs thalassémie et autres maladies rares du globule rouge et de l'érythropoïése, Créteil

Sponsors
All Listed Sponsors
collaborator

Filière de santé maladies rares MCGRE

UNKNOWN

collaborator

Fédération des malades drépanocytaires et thalassémiques SOS Globi

UNKNOWN

collaborator

Genetix Biotherapeutics Inc.

INDUSTRY

lead

Argo Sante

OTHER

NCT04413539 - Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living with Sickle- Cell Disease in France | Biotech Hunter | Biotech Hunter